Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081561 | 0.95 | LIPG (0.51) | LIPGCYP3A4KMT2ATLR8MEN1 | |
| SCHEMBL7889302 | 0.93 | LIPG (0.54) | LIPGCYP3A4KMT2AMEN1NR1I2 | |
| SCHEMBL7899209 | 0.93 | LIPG (0.54) | LIPGCYP3A4KMT2AMEN1NR1I2 | |
| Iodide SCHEMBL8515618 | 0.91 | LIPG (0.53) | LIPGCYP3A4KMT2AMEN1NR1I2 | |
| SCHEMBL7896315 | 0.89 | KMT2A (0.42) | LIPGCYP3A4KMT2ALMNAMAPT | |
| SCHEMBL9791249 | 0.83 | LIPG (0.46) | LIPGCYP3A4CYP2D6CYP2C9KMT2A | |
| SCHEMBL7085183 | 0.81 | LIPG (0.44) | LIPGCYP3A4CYP2D6CYP2C9TLR8 | |
| SCHEMBL1002853 | 0.81 | MAPT (0.53) | LIPGCYP3A4KMT2AMEN1NR1I2 | |
| SCHEMBL5511463 | 0.81 | CYP3A4 (0.45) | LIPGCYP3A4CYP2D6CYP2C9KMT2A | |
| SCHEMBL18929919 | 0.81 | LIPG (0.44) | LIPGCYP3A4CYP2D6CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801861-B2 | Antimicrobial substituted thiazoles and methods of use | PURDUE RESEARCH FOUNDATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160243088-A1 | ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2016-08-25 | — | — | US | disclosed |
| US-9353072-B2 | Antimicrobial substituted thiazoles and methods of use | PURDUE RESEARCH FOUNDATION (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140121249-A1 | ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE | PURDUE RESEARCH FOUNDATION | 2014-05-01 | — | — | US | disclosed |
| CN-100475810-C | Novel 2-arylthiazole compounds as pparalpha and ppargamma agonists | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | CN | disclosed |
| EP-1962605-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| CN-1678596-A | Novel 2-arylthiazole compounds as PPAR alpha and PPAR gamma agonists | HOFFMANN LA ROCHE (CH) | 2005-10-05 | — | — | CN | disclosed |
| US-6277998-B1 | REACTING 2-CYANO-4-OXO-4H-BENZOPYRAN COMPOUND WITH HYDROGEN SULFIDE AND THEN REACTING PROUDCT WITH ALKYL HALIDE; REACTING THE PRODUCT WITH HYDRAZINE OR ITS SALT AND THEN WITH NITROUS ACID COMPOUND TO OBTAIN TETRAZOLE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-21 | — | — | US | disclosed |
| US-6191289-B1 | REACTING A 4-OXO-4H-BENZOPYRAN GROUP SUBSTITUTED WITH AMIDE OR A PHENYL GROUP IN ITS 2 POSITION IS REACTED WITH ANHYDROUS HYDRAZINE OR SALT IN PRESENCE OF CATALYST FOLLOWED BY REACTING WITH NITROUS ACID OR SALT TO FORM TETRAZOLE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-02-20 | — | — | US | disclosed |
| US-5874593-A | SULFUR CONTAINING AMIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-02-23 | — | — | US | disclosed |
| EP-0711762-A1 | PROCESS FOR PRODUCING TETRAZOLE COMPOUND AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121249-A1 | ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE | CLPP, ELANE, NOD2 | LIPG 2909/4885CYP3A4 1337/4885CYP2D6 760/4885 |
| US-20160243088-A1 | ANTIMICROBIAL SUBSTITUTED THIAZOLES AND METHODS OF USE | CLPP, ELANE, NOD2 | LIPG 2909/4885CYP3A4 1337/4885CYP2D6 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.